AR049053A1 - Metodo, formulacion y aparato para administracion transdermica de agentes inmunologicamente activos - Google Patents
Metodo, formulacion y aparato para administracion transdermica de agentes inmunologicamente activosInfo
- Publication number
- AR049053A1 AR049053A1 ARP050102040A ARP050102040A AR049053A1 AR 049053 A1 AR049053 A1 AR 049053A1 AR P050102040 A ARP050102040 A AR P050102040A AR P050102040 A ARP050102040 A AR P050102040A AR 049053 A1 AR049053 A1 AR 049053A1
- Authority
- AR
- Argentina
- Prior art keywords
- immunologically active
- active agent
- formulation
- appliance
- active agents
- Prior art date
Links
- 239000013543 active substance Substances 0.000 title abstract 9
- 238000000034 method Methods 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 229960003971 influenza vaccine Drugs 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000011248 coating agent Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 238000009295 crossflow filtration Methods 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000007921 spray Substances 0.000 abstract 1
- 238000001694 spray drying Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
Un método para la formulacion de un agente inmunologicamente activo y un aparato para la administracion del mismo. El método comprende los pasos de proveer un agente inmunologicamente activo amplio, someter el agente inmunologicamene activo amplio a una filtracion de flujo tangencial para proveer una solucion del agente inmunologicamente activo, agregar al menos un excipiente a la solucion del agente inmunologicamente activo y secar por aspersion la solucion del agente para formar un agente inmunologicamente activo como producto. El aparato comprende una pieza de microproyeccion que incluye una pluralidad de microproyecciones que tienen un recubrimiento biocompatible dispuesto sobre la misma que incluye un agente inmunologicamente activo secado por aspersion. En una realizacion preferida el agente inmunologicamente activo comprende una vacuna contra la influenza, más preferiblemente una vacuna contra la influenza de virus fraccionado.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57286104P | 2004-05-19 | 2004-05-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR049053A1 true AR049053A1 (es) | 2006-06-21 |
Family
ID=35394844
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050102040A AR049053A1 (es) | 2004-05-19 | 2005-05-18 | Metodo, formulacion y aparato para administracion transdermica de agentes inmunologicamente activos |
Country Status (13)
Country | Link |
---|---|
US (1) | US20050266011A1 (es) |
EP (1) | EP1747672A4 (es) |
JP (1) | JP2008507590A (es) |
CN (1) | CN101433091A (es) |
AR (1) | AR049053A1 (es) |
AU (1) | AU2005242409A1 (es) |
CA (1) | CA2566759A1 (es) |
IL (1) | IL179378A0 (es) |
MX (1) | MXPA06013490A (es) |
NO (1) | NO20065792L (es) |
TW (1) | TW200608992A (es) |
WO (1) | WO2005112463A2 (es) |
ZA (1) | ZA200610654B (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020193729A1 (en) * | 2001-04-20 | 2002-12-19 | Cormier Michel J.N. | Microprojection array immunization patch and method |
GB0505518D0 (en) * | 2005-03-17 | 2005-04-27 | Chiron Srl | Combination vaccines with whole cell pertussis antigen |
US8168206B1 (en) * | 2005-10-06 | 2012-05-01 | Allergan, Inc. | Animal protein-free pharmaceutical compositions |
CA2801151A1 (en) * | 2010-06-01 | 2011-12-08 | Novartis Ag | Concentration of vaccine antigens with lyophilization |
KR20220163497A (ko) * | 2010-06-01 | 2022-12-09 | 노파르티스 아게 | 동결건조하지 않는 인플루엔자 백신 항원의 농축 |
US9517205B2 (en) | 2010-08-20 | 2016-12-13 | Seqirus UK Limited | Soluble needle arrays for delivery of influenza vaccines |
RU2013143149A (ru) * | 2011-02-24 | 2015-03-27 | Пэксвэкс, Инк. | Составы, пригодные для вакцин, получаемых сушкой распылением |
GB201106802D0 (en) | 2011-04-21 | 2011-06-01 | Allergy Therapeutics Ltd | Process for preparing vaccine composition |
WO2015050177A1 (ja) * | 2013-10-03 | 2015-04-09 | 日東電工株式会社 | インフルエンザワクチン乾燥製剤、及び、インフルエンザワクチン乾燥製剤の製造方法 |
WO2015093452A1 (ja) * | 2013-12-16 | 2015-06-25 | 武田薬品工業株式会社 | マイクロニードル |
JP7217700B2 (ja) | 2016-09-13 | 2023-02-03 | アラーガン、インコーポレイテッド | 安定化非タンパク質クロストリジウム毒素組成物 |
JP2020519666A (ja) * | 2017-05-15 | 2020-07-02 | ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. | 安定性のウイルス含有組成物 |
WO2020016322A1 (en) | 2018-07-19 | 2020-01-23 | Glaxosmithkline Biologicals Sa | Processes for preparing dried polysaccharides |
JP2023522699A (ja) * | 2020-04-22 | 2023-05-31 | エマージェクス ユーエスエー コーポレーション | コロナウイルスワクチンでコーティングされた微小突起を有する経皮活性剤送達デバイス |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3964482A (en) * | 1971-05-17 | 1976-06-22 | Alza Corporation | Drug delivery device |
BE795384A (fr) * | 1972-02-14 | 1973-08-13 | Ici Ltd | Pansements |
GB1488800A (en) * | 1973-11-29 | 1977-10-12 | Wellcome Found | Influenza vaccines |
US5080646A (en) * | 1988-10-03 | 1992-01-14 | Alza Corporation | Membrane for electrotransport transdermal drug delivery |
US5147296A (en) * | 1988-10-03 | 1992-09-15 | Alza Corporation | Membrane for electrotransport transdermal drug delivery |
US5169382A (en) * | 1988-10-03 | 1992-12-08 | Alza Corporation | Membrane for electrotransport transdermal drug delivery |
EP0429842B1 (en) * | 1989-10-27 | 1996-08-28 | Korea Research Institute Of Chemical Technology | Device for the transdermal administration of protein or peptide drug |
US6582728B1 (en) * | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
WO1996037155A1 (en) * | 1995-05-22 | 1996-11-28 | Silicon Microdevices, Inc. | Micromechanical device and method for enhancing delivery of compounds through the skin |
WO1997048440A1 (en) * | 1996-06-18 | 1997-12-24 | Alza Corporation | Device for enhancing transdermal agent delivery or sampling |
KR100561892B1 (ko) * | 1997-12-11 | 2006-03-16 | 알자 코포레이션 | 경피성 작용제 유동률을 증진시키기 위한 장치 |
KR100572539B1 (ko) * | 1997-12-11 | 2006-04-24 | 알자 코포레이션 | 경피성 작용제 유동률을 증진시키기 위한 장치 |
US6091975A (en) * | 1998-04-01 | 2000-07-18 | Alza Corporation | Minimally invasive detecting device |
US6284282B1 (en) * | 1998-04-29 | 2001-09-04 | Genentech, Inc. | Method of spray freeze drying proteins for pharmaceutical administration |
RU2282468C2 (ru) * | 2000-10-26 | 2006-08-27 | Алза Корпорейшн | Устройство для трансдермальной доставки лекарственных средств, имеющее микровыступы с покрытием |
WO2002074173A1 (en) * | 2001-03-16 | 2002-09-26 | Alza Corporation | Method and apparatus for coating skin piercing microprojections |
US20020193729A1 (en) * | 2001-04-20 | 2002-12-19 | Cormier Michel J.N. | Microprojection array immunization patch and method |
WO2003049670A2 (en) * | 2001-07-27 | 2003-06-19 | Immuno-Rx, Inc. | Adjuvant formulations for bacterial and virus vaccines and method of making same |
WO2003087335A2 (en) * | 2002-04-11 | 2003-10-23 | Medimmune Vaccines, Inc. | Preservation of bioactive materials by spray drying |
US20050220854A1 (en) * | 2004-04-01 | 2005-10-06 | Yuh-Fun Maa | Apparatus and method for transdermal delivery of influenza vaccine |
CA2562642A1 (en) * | 2004-04-13 | 2005-11-03 | Alza Corporation | Apparatus and method for transdermal delivery of multiple vaccines |
-
2005
- 2005-04-21 AU AU2005242409A patent/AU2005242409A1/en not_active Abandoned
- 2005-04-21 WO PCT/US2005/014008 patent/WO2005112463A2/en active Application Filing
- 2005-04-21 MX MXPA06013490A patent/MXPA06013490A/es unknown
- 2005-04-21 CN CNA2005800237976A patent/CN101433091A/zh active Pending
- 2005-04-21 EP EP05779669A patent/EP1747672A4/en not_active Withdrawn
- 2005-04-21 JP JP2007527244A patent/JP2008507590A/ja active Pending
- 2005-04-21 CA CA002566759A patent/CA2566759A1/en not_active Abandoned
- 2005-04-21 US US11/112,311 patent/US20050266011A1/en not_active Abandoned
- 2005-05-18 AR ARP050102040A patent/AR049053A1/es not_active Application Discontinuation
- 2005-05-19 TW TW094116367A patent/TW200608992A/zh unknown
-
2006
- 2006-11-16 IL IL179378A patent/IL179378A0/en unknown
- 2006-12-14 NO NO20065792A patent/NO20065792L/no not_active Application Discontinuation
- 2006-12-18 ZA ZA200610654A patent/ZA200610654B/en unknown
Also Published As
Publication number | Publication date |
---|---|
TW200608992A (en) | 2006-03-16 |
IL179378A0 (en) | 2007-03-08 |
NO20065792L (no) | 2007-02-14 |
WO2005112463A3 (en) | 2009-05-14 |
CA2566759A1 (en) | 2005-11-24 |
EP1747672A4 (en) | 2010-02-17 |
JP2008507590A (ja) | 2008-03-13 |
WO2005112463A2 (en) | 2005-11-24 |
CN101433091A (zh) | 2009-05-13 |
AU2005242409A1 (en) | 2005-11-24 |
MXPA06013490A (es) | 2007-06-12 |
EP1747672A2 (en) | 2007-01-31 |
US20050266011A1 (en) | 2005-12-01 |
ZA200610654B (en) | 2008-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR049053A1 (es) | Metodo, formulacion y aparato para administracion transdermica de agentes inmunologicamente activos | |
SV2016005320A (es) | Formulaciones y mã‰todos de tratamiento con queratina | |
CL2018000706A1 (es) | Derivados de pirazolopirimidina como inhibidores btk para el tratamiento del cancer. | |
CU20190005A7 (es) | Goma de mascar administrable oralmente o formulaciones acuosas que comprenden un agente farmacéutico | |
CO6300964A2 (es) | Una composicion farmaceutica que comprende una combinacion de un agente quimioterapeutico y un anticuerpo 3 antiglipicano | |
AR060836A1 (es) | Un disco trans-mucosa para administrar un agente activo, una composicion trans-mucosa y el metodo de administracion obtenido | |
AR055838A1 (es) | Formulaciones para microproyecciones recubiertas que tienen solubilidad controlada | |
ECSP088560A (es) | Formulacion de liberacion sostenida que comprende octreotida y dos o mas polimeros de polilactido-co-glicolido | |
CL2009000902A1 (es) | Composicion que comprende posaconazol disuelto o disperso molecularmente en un polimero derivado de hidroxipropilcelulosa; formulacion farmaceutica que comprende a la composion; un proceso para preparar a la composicion mediante fusioextrusion; y su uso para tratar una infeccion micotica. | |
ECSP21023398A (es) | Dosis unitaria de vacuna contra el dengue y administración de esta | |
PE20151588A1 (es) | Vacuna contra el virus del dengue | |
AR046608A1 (es) | Aparato para la administracion transdermica de agentes a base de nicotina | |
ECSP14023048A (es) | Agentes terapéuticos para administración subcutánea optimizados | |
CL2012001844A1 (es) | Metodo para el tratamiento del sindrome de apnea obstructiva del sueño que comprende la administración de un inhibidor de la anhidrasa carbónica y un agente adicional seleccionado de modafinilo, agente sedante no benzodiazepina, y combinaciones de los mismos; una formulacion farmacéutica; una preparacion farmaceutica empaquetada. | |
CY1120793T1 (el) | Μεθοδοι θεραπευτικης αγωγης παθησεων που αφορουν μαλλια | |
CY1125075T1 (el) | Εκχυλισμα salvia haenkei σαν δραστικος παραγοντας στις διαδικασιες επανεπιθηλιωσης και επουλωσης ιστων | |
CL2018003682A1 (es) | Composición farmacéutica oral, que comprende un agente farmacéuticamente activo, al menos un polímero catiónico bioadhesivo y al menos dos polímeros aniónicos. | |
CL2021001636A1 (es) | Composición farmacéutica para el tratamiento de la hipertensión arterial pulmonar | |
CL2019003463A1 (es) | Composición farmacéutica y forma de dosis farmacéutica que comprenden (e)-4-(2-(aminometil)-3-fluoroaliloxi)-n-ter-butilbenzamida, proceso para su preparación, métodos para tratamiento y usos de estas. | |
NI201000181A (es) | Utilización de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administración de dronedarona. | |
CL2009002204A1 (es) | Composicion intravenosa biocompatible que comprende un factor de coagulacion incluido en microparticulas de acido alginico o sales del mismo. | |
PA8615501A1 (es) | Formulaciones farmaceuticas transdermicas | |
CO2022002493A2 (es) | Nanoemulsion de ácido 18p-glicirretínico | |
ES2507517T3 (es) | Agente profiláctico o terapéutico para trastorno de déficit de atención con hiperactividad | |
CL2014003326A1 (es) | Formulación antioxidante inyectable de uso intravenoso de ascorbato de sodio - en altas dosis, y n-acetilcisteína como agentes oxidantes, y deferoxamina como agentes quelante de hierro, más excipientes farmacéuticos; método para su administración y uso en prevenir el daño por repertfusión en pacientes con inferto agudo del miocardío, sometidos a angioplastia caronaria primaria; y kit que la contiene. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |